 7. All females of childbearing potential must use an effective barrier method of contraception either an intrauterine contraceptive device IUCD or double barrier method using condoms or a diaphragm plus spermicide during the treatment period and for at least 1 month thereafter. Male subjects should use a barrier method of contraception during the treatment period and for at least 3 months thereafter. Female subjects should avoid the use of estrogen-containing contraceptives, since romidepsin may reduce the effectiveness of estrogen-containing contraceptives. An in vitro binding assay determined that romidepsin competes with β-estradiol for binding to estrogen receptors. 